


PHARMACEUTICAL 2022


## Summit Therapeutics Inc. Rank 284 of 466













The relative strengths and weaknesses of Summit Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Summit Therapeutics Inc. compared to the market average is the variable Other Liabilities, increasing the Economic Capital Ratio by 28% points. The greatest weakness of Summit Therapeutics Inc. is the variable Research and Development, reducing the Economic Capital Ratio by 72% points.

The company's Economic Capital Ratio, given in the ranking table, is 77%, being 0.65% points below the market average of 78%.

Input Variable	Value in 1000 USD
Assets, Current	97,312
Cost of Goods Sold	0
Intangible Assets	12,408
Liabilities, Current	25,623
Liabilities, Non-Current	4,467
Other Assets	2,960
Other Compr. Net Income	1,597
Other Expenses	0
Other Liabilities	0
Other Net Income	-2,416
Other Revenues	22,777
Property and Equipment	694
Research and Development	85,352
Selling, General and Administrative Expense	23,611

Output Variable	Value in 1000 USD
Assets	113,374
Liabilities	30,090
Expenses	108,963
Revenues	22,777
Stockholders Equity	83,284
Net Income	-88,602
Comprehensive Net Income	-87,804
Economic Capital Ratio	77%

